HIGHLIGHTS
- who: Namhee Yu from the (UNIVERSITY) have published the article: Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer, in the Journal: (JOURNAL)
- what: Our well-established pharmacogenomic platform effectively predicted drugs and response mechanisms for refractory lung cancer.
- how: To bridge this gap in this study the authors developed PDC models using mainly the pleural effusions of refractory lung cancer patients. The authors investigated the transcriptome characteristics of SCLC from differentially expressed gene (DEG) analysis to compare SCLC with NSCLC using limma . The . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.